Veterinary Medicines

Veloxa Chewable Tablets for Dogs

Authorised
  • Febantel
  • Pyrantel
  • Praziquantel
Download as PDF

Product identification

Medicine name:
Veloxa Chewable Tablets for Dogs
Veloxa 150/144/50 mg tyggetabletter til hund
Active substance:
  • Febantel
  • Pyrantel
  • Praziquantel
Target species:
  • Dog
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Febantel
    150.00
    milligram(s)
    /
    1.00
    Tablet
  • Pyrantel
    50.00
    milligram(s)
    /
    1.00
    Tablet
  • Praziquantel
    50.00
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Chewable tablet
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QP52AA51
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Norway
Package description:
  • PVC/Aluminium/Polyamide blister-forming laminate with aluminium lidding foil containing 2 or 8 chewable tablets. Box containing 52 blister strips of 2 chewable tablets (104 chewable tablets)
  • PVC/Aluminium/Polyamide blister-forming laminate with aluminium lidding foil containing 2 or 8 chewable tablets. Box containing 13 blister strips of 8 chewable tablets (104 chewable tablets)
  • PVC/Aluminium/Polyamide blister-forming laminate with aluminium lidding foil containing 2 or 8 chewable tablets. Box containing 1 blister strip of 2 chewable tablets (2 chewable tablets)
  • PVC/Aluminium/Polyamide blister-forming laminate with aluminium lidding foil containing 2 or 8 chewable tablets. Box containing 2 blister strips of 2 chewable tablets (4 chewable tablets)
  • PVC/Aluminium/Polyamide blister-forming laminate with aluminium lidding foil containing 2 or 8 chewable tablets. Box containing 1 blister strips of 8 chewable tablets (8 chewable tablets)

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Generic application (Article 13(1) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Lavet Kft.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Lavet Kft.
Responsible authority:
  • Norwegian Medical Products Agency
Authorisation number:
  • 12-9036
Date of authorisation status change:
Reference member state:
  • Hungary
Procedure number:
  • HU/V/0116/001
Concerned member states:
  • Austria
  • Belgium
  • Finland
  • France
  • Germany
  • Greece
  • Ireland
  • Italy
  • Luxembourg
  • Netherlands
  • Norway
  • Portugal
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Norwegian (PDF)
Published on: 3/11/2025
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Norwegian (PDF)
Published on: 3/11/2025
Download